Market evolution: Hormonal contraceptives (CN 300660) — 2015–2025

Introduction

This report examines the evolution of EU trade in chemical contraceptive preparations (CN 300660) over the 2015–2025 period. The product category covers hormonal contraceptives based on hormones, prostaglandins, thromboxanes, leukotrienes, their derivatives and structural analogues, as well as spermicide-based preparations (Scope & Definitions).

Over the decade, the EU consolidated its position as a major global exporter of hormonal contraceptives, with export values rising from €1.47 billion to €2.19 billion (+49.6%) and export volumes climbing even more steeply from 7,426 to 12,727 tonnes (+71.4%). Meanwhile, imports fell sharply in both value and volume. The resulting trade surplus widened from €1.44 billion to €2.18 billion, while net import reliance deepened from −45.6% to −472%, confirming the EU's structural role as a net exporter of this product.

1. A steep rise in EU export volumes, driven by price competition and US demand

Export volumes grew much faster than export values

Between 2015 and 2025, EU exports of CN 300660 increased by 71.4% in quantity but only 49.6% in value, implying that the average unit export price declined by 12.7% — from €197,573 per tonne in 2015 to €172,447 per tonne in 2025 (General Overview). This suggests that EU exporters expanded volumes partly through more competitive pricing, possibly reflecting increased production capacity and economies of scale. EU production value of hormonal contraceptives grew from €1.36 billion to €2.1 billion over the period (+54.6%), supporting this interpretation (Market Structure).

The United States became the dominant export destination

The most striking shift in EU export markets was the surge in shipments to the United States. US-bound exports rose from €324 million in 2015 to over €1 billion in 2025 — an increase of 213.1% — making the US by far the largest single destination for EU hormonal contraceptives. This growth likely reflects both supply-chain reconfiguration and the increasing integration of EU pharmaceutical manufacturers into the North American market. The US market, however, also displayed the highest export volatility among major partners, with a coefficient of variation of 0.97, suggesting that year-to-year flows were quite unstable (Volatility & Shocks).

Export concentration increased sharply

As the US grew in importance, the EU's export market became significantly more concentrated. The Herfindahl–Hirschman Index (HHI) for export value rose from 717 in 2015 to 2,295 in 2025 — a 220.3% increase — moving the distribution from a broadly diversified pattern toward a more concentrated one (General Overview). While concentration remains below the threshold typically considered high-risk (2,500+), the trend implies growing dependency on a smaller number of destination markets, particularly the United States.

2. A dramatic contraction in imports, with shifting supplier geography

Imports fell in value, volume and unit price

EU imports of hormonal contraceptives declined dramatically over the decade. In value terms, imports dropped from €30.6 million to €11.6 million (−62.2%); in volume, from 309 tonnes to 207 tonnes (−33.0%); and in average import price, from €99,106 per tonne to €55,867 per tonne (−43.6%). The simultaneous decline across all three dimensions points to a structural reduction in the EU's reliance on external supply, consistent with the expansion of domestic production (General Overview).

Switzerland disappeared as a supplier; India emerged as the leading source

The most dramatic change on the import side was the collapse of Swiss-origin imports, which fell from €16.6 million in 2015 to just over €1,000 in 2025 — effectively a full exit. This near-total drop may reflect the relocation of Swiss pharmaceutical production into the EU or the termination of specific trade arrangements. Meanwhile, India emerged as the dominant import source, with its share rising from €3.8 million to €7.7 million (+104.1%), making India the EU's top import partner by 2025. The United Kingdom also saw its exports to the EU fall sharply (−96.2%), likely connected to post-Brexit regulatory and trade realignments.

Import concentration also increased, but on a smaller scale

The HHI for import value rose from 3,601 to 4,921 (+36.7%), indicating that imports were already somewhat concentrated in 2015 and became even more so by 2025. In volume terms, the concentration increase was steeper (+106.3%), reflecting the growing share of India in import volumes. Despite this, the absolute scale of imports remains modest — under €12 million by 2025 — limiting the strategic significance of this concentration for the EU market as a whole (Market Structure).

3. Internal EU specialisation became more uneven, while a major export shock hit Canada

Export specialisation consolidated around a few Member States

Among EU Member States, Hungary displayed the highest degree of export specialisation in 2025, with a Revealed Symmetric Comparative Advantage (RSCA) of 0.79 and an RCA of 8.72 — meaning Hungary exports hormonal contraceptives at nearly nine times the rate its overall trade profile would predict. Ireland (RSCA 0.35), the Netherlands (0.22), and Germany (0.16) also showed significant specialisation. At the other end of the spectrum, several Member States — including Latvia, Croatia, Bulgaria, and Slovakia — had essentially zero export activity in this product, with RSCA values at or near −1.0 (Market Structure).

The Netherlands and Spain emerged as fast-growing exporters

Among the top EU exporting Member States, the Netherlands saw the largest absolute growth, rising from €446 million to €1.01 billion (+126.4%) and becoming the single largest EU exporter by 2025. Spain's growth was even more striking in relative terms: from €25 million to €262 million (+959.2%), catapulting it into the top tier. By contrast, Belgium's exports declined from €337 million to €209 million (−38.2%), and Ireland's fell from €70 million to €7.3 million (−89.6%). These shifts suggest a rebalancing of production capacity within the EU, with the Netherlands, Germany, Hungary, and Spain consolidating as the principal exporting hubs.

A pronounced price shock to Canada in 2018 stands out

The volatility analysis reveals a notable price shock in EU exports to Canada in 2018. The event registered an abnormality score of 3,884.6 — by far the highest detected — with a price shift of +296.2% and a value share of 5.3% of total exports that year. Given its exceptional magnitude and the pharmaceutical nature of the product, this event likely reflects a one-off supply disruption, a major contract renegotiation, or a regulatory-driven reallocation of shipments rather than a sustained market trend. Two smaller price shocks were detected in exports to Israel (2019) and Malaysia (2021), but these were of much lower intensity (Volatility & Shocks).

Conclusion

Over the 2015–2025 period, the EU's trade in hormonal contraceptives (CN 300660) underwent a decisive shift toward export dominance. Export volumes nearly doubled, the trade surplus widened to €2.18 billion, and net import reliance deepened to −472%, confirming the EU as a structural net supplier to global markets. This was achieved alongside a 12.7% decline in export unit prices, suggesting that EU manufacturers competed not only on quality but increasingly on cost.

The geographic pattern of trade evolved substantially. On the export side, the United States became the overwhelmingly dominant destination, absorbing nearly half of all EU exports by value. This concentration — reflected in a sharply rising export HHI — introduces a new vulnerability: any disruption in US demand could disproportionately affect EU producers. On the import side, Switzerland's near-complete exit and India's emergence as the leading supplier reshaped the sourcing landscape, while the absolute scale of imports shrank to a fraction of exports.

Within the EU, specialisation became more pronounced, with the Netherlands, Germany, Hungary, and Spain emerging as the principal exporting hubs. The Netherlands alone grew its exports to over €1 billion, while Spain's tenfold increase signals the rise of new production centres. Meanwhile, several traditional exporters (Belgium, Ireland) saw significant declines, suggesting an ongoing reorganisation of production capacity.

Overall, the EU's hormonal contraceptive sector has strengthened its global competitive position, but increasing market concentration — both in terms of export destinations and intra-EU specialisation — warrants attention from a trade-resilience perspective.